Nilai titik potong kadar angiostatin urin sebagai prediktor keganasan pada tumor ovarium epitel
DAFTAR PUSTAKA
1. Antoniou A, Pharaoh PD, Narod S, et al. Average risks of breast and
ovarian cancer associated with BRCA1 or BRCA2 mutations detected
in case series unselected for family history: a combined analysis of 22
studies. Am J Hum Genet.2003;72(5):1117-30
2. World Cancer Research Fund / American Institute for Cancer
Research. Continuous Update Project Report. Food, Nutrition,
Physical Activity, and the Prevention of Ovarian Cancer 2014.
Available athttp://www.dietandcancerreport.org/cup/cup_resources.php
3. Jemal A, Siegel R, Ward E et al. Cancer statistics. CA Cancer J. Clin.
2008; 58(2):71–96.
4. du Bois A, Rochon J, Pfisterer J, Hoskins WJ. Variations in institutional
infrastructure, physician specialization and experience, and outcome in
ovarian cancer: a systematic review. Gynecol Oncol.2009;112:422-36.
5. Palmer C, et al. Systematic evaluation of candidate blood markers for
detecting ovarian cancer. PLoS One.2008;3:e2633
6. Blast L. Antigen cancer CA-125 in ovarian cancer. Am J Hum
Genet.1983;2
7. Zurawski VR, et al. An initial analysis of preoperative serum CA-125
levels in patients with early stage ovarian carcinoma. Gynecol
Oncol.1988;30:7-14
8. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A
risk of malignancy index incorporating CA-125, ultrasound and
menopausal status for the accurate preoperative diagnosis of ovarian
cancer. Br J Obstet Gynecol.1990;97:922-9
9. Van Holsbeke C, et al. Ultrasound methods to distinguish between
malignant and benign adnexal masses in the hands of examiners with
different
levels
of
experience.
Ultrasound
Obstet
Gynecol.2009;34:454-61.
10. Ferrara N. Vascular endothelial growth factor: basic science and
clinical progress. Endocr Rev.2004;25(4):581-611.
65
11. Zetter BR. Angiogenesis and tumor metastatis. Children’s Hospital.
Harvard Medical School. Boston. Massachusetts.1998;49:407-27
12. Oklu R, Walker TG, Wicky S, Hesketh R. Angiogenesis and current
antiangiogenic strategies for the treatment of cancer. Department of
Biochemistry University of Cambrige. United Kingdom.2010;21:19711805
13. Eskens FA. Angiogenesis inhibitors in clinical development; where are
we now and where are we going? Br J Cancer.2004;90:1-7.
14. Hazelton D, Nicosia RF, Nicosia SV. Vascular endothelial growth
factor levels in ovarian cyst fluid correlate with malignancy. Clin
Cancer Res.1999;5(4):823-9.
15. Yabushita H, Noguchi M, Obayashi Y, Kishida T, Noguchi Y,
Sawaguchi K, et al. Angiostatin expression in ovarian cancer. Oncol
Rep.2003;10(5):1225-30.
16. Urano T, Chibber B. A., Castellino F. J. The reciprocal effects of
epsilon-aminohexanoic acid and chloride ion on the activation of
human [Glu1]plasminogen by human urokinase. Proc. Natl. Acad. Sci.
U.S.A.1987;84:4031–4
17. Drenberg CD, Saunders BO, Wilbanks GD, Chen R, Nicosia RF, Kruk
PA, et al. Urinary angiostatin levels are elevated in patients with
epithelial ovarian cancer. Gynecologic Oncology.2010;117:117-124.
18. Damayana S. Perbedaan kadar angiostatin urin pada tumor ovarium
epitel jinak dan tumor ovarium epitel ganas. Tesis Peserta Pendidikan
Dokter Spesialis Obstetri dan Ginekologi Universitas Sumatera
Utara.2014.
19. Cunningham FG, Gant NF, Leveno KJ, Gilstrap LC, Hauth JC,
Wenstrom KD. Obstetri Williams Edisi ke-21 Vol. 2. Jakarta : ECG;
2004. p. 934,1035-7.
20. Berek JS, Satima N. Ovarian and fallopian tube cancer. Berek &
Novak’s Gynecology. Lippincott William and Wilkins. 14th ed. 2007:
1457-1503
21. WHO, GLOBOCAN, International agency of research and cancer.2008
22. FIGO Committee on Gynecologic Oncology, Denny L et al. Staging
classification and clinical practice guidelines for gynaecologic
cancers.2009.
66
23. Kurman RJ, Shih le-Ming. Pathogenesis of ovarian cancer: lessons
from morphology and molecular biology and their clinical implications.
Int J Gynecol Pathol.2008;27(2):151-60
24. Brohet RM, Goldgar DE, Easton DF, et al. Oral contraceptives and
breast cancer risk in the international BRCA1/2 carrier cohort study: a
report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS
collaborating group. J Clin Oncol.2007;25:3831-6
25. Rostgaard K. Does pregnancy induce the shedding of premalignat
ovarian cells? Epidemiology.2003;14:168-173
26. Whittermore AS. Characteristic relating to ovarian cancer risk,
Collaborating ovarian cancer group. Am J Epidemiol.1992;136:11841203
27. Cannistra SA, Gershenson DM, Recht A. Ovarian cancer, peritoneal
carcinoma and fallopian tube carcinoma. In: DeVita VT, Hellman S,
Rosenberg SA, eds. Cancer: Principles and practice of oncology. 8th
ed. Philadelpia, PA: Lippincott Williams & Wilkins; 2008:1569-94
28. Lynch HT, Casey MJ, Snyder CL, et al. Hereditary ovarian carcinoma:
Heterogeneity, molecular genetics, pathology and management and
hereditary
nonpolyposis
colorectal
cancer
(HNPCC).
Mol
Oncol.2009;3:97-137
29. Scully R, Sobin L. Histological typing of ovarian tumours, volume 9.
New York: Springer Berlin,1999.
30. Saifuddin, Abdul Bari, dkk. Ilmu Kebidanan Sarwono Prawirohardjo.
Jakarta: PT Bina Pustaka Sarwono Prawirohardjo. 2010.
31. Chen SS, Bochner R. Assesment of morbidity and mortality in primary
cytoreductive surgery for advanced ovarian carcinoma. Gynecol
Oncol.1985;20(2):190-5
32. Olivier RI, Lubsen-Brandsma MA, Verhoef S, et al. CA-125 and
transvaginal ultrasound monitoring in high risk women cannot prevent
the
diagnosis
of
advanced
ovarian
cancer.
Gynecol
Oncol.2006;100(1):20-26
33. Braun AH, Coffey RJ. Lysophosphatidic acid, a disintegrin and
metalloprotease-17 and heparin-binding epider- mal growth factor-like
growth factor in ovarian cancer: the first word, not the last. Clinical
Cancer Research.2005;11:4639–43.
67
34. Levine HA, Pamuk S, Sleeman BD, Hamilton MN. Mathematical
Modelling of Tumour Angiogenesis and the Action of Angiostatin as a
Protease Inhibitor. J Theoritical Med.2002; 4(2):133-45.
35. Shirakawa K, et al. Vasculogenic mimicry and pseudo-comedo
formation in breast cancer. Int J Cancer.2002;99:821–28
36. Baluk P, et al. Cellular abnormalities of blood vessels as targets in
cancer. Curr Opin Genet Dev.2005;15:102–11.
37. Cao Y. Therapeutic potentials of angiostatin in the treatment of cancer.
Haematologica.1999;84:643-650.
38. Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic
target for ovarian cancer therapy. Nature Clin Prac Oncol.2006; 5:194204.
39. Sim BKL, O'Reilly MS, Liang H, Fortier AH, He W, Madsen JW, et al. A
recombinant human angiostatin protein inhibits experimental primary
and metastatic cancer. Cancer Res.1997;57:1329–34.
40. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J
Med.1971;285(1):182-6.
41. Walter JJ, Sane DC. Angiostatin binds to smooth muscle cells in the
coronary artery and inhibits smooth muscle cell proliferation and
migration In vitro. ArteriosclerThromb Vasc Biol.1999;19:2041-8.
42. Morikawa W, Yamamoto K, Ishikawa S, Takemoto S, Ono M, Fukushi
J, Naito S, Nozaki C, Iwanaga S, and Kuwano M. Angiostatin
generation by cathepsin D secreted by human prostate carcinoma
cells. J. Biol. Chem.2000;275: 38912–20.
43. Ji WR, Castellino FJ, Chang Y, Deford ME, Gray H, Villarreal X, et al.
Characterization of kringle domains of angiostatin as antagonists of
endothelial cell migration, an important process in angiogenesis.
FASEB.1998;12(15):1731-8.
44. Cao Y, Chen A, An SS, Ji RW, Davidson D, Llinas M: Kringle 5 of
plasminogen is a novel inhibitor of endothelial cell growth. J Biol
Chem.1997;272(36):22924-8.
45. Wahl ML, Kenan DJ, Gronow GM, Pizzo SV. Angiostatin's molecular
mechanism: aspects of specificity and regulation elucidated. J Cell
Biochem.2005;96(2):242-61.
46. Warejcka D. Angiostatin used as an assay standard in a cell
proliferation assay. Biochem. J.2005;392:703–12.
68
47. Soff GA. Angiostatin and angiostatin-related
Metastasis Rev.2000;19(1-2):97-107.
proteins.
Cancer
48. O'Reilly MS. et al. Angiostatin: a novel angiogenesis inhibitor that
mediates the suppression of metastases by a Lewis lung carcinoma.
Cell.1994;79:315-28.
49. Cao R, Wu HL, Veitonmaki N, Linden P, Farnebo J, Shi GY, et al:
Suppression of angiogenesis and tumor growth by the inhibitor K1–5
generated by plasmin-mediated proteolysis. Proc Natl Acad Sci
USA.1999;96:5728-5733.
50. Schulter V, et al. Impact of apolipoprotein(a) on in vitro angiogenesis.
Arterioscler Thromb Vasc Biol.2001;21:433-8.
51. Mowery YM, Pizzo
2009;114(9):1727-8
SV.
The
antitumorigenic
trifecta.
Blood
52. Chi SL, Pizzo SV. Angiostatin Is Directly Cytotoxic to Tumor Cells at
Low Extracellular pH: A Mechanism Dependent on Cell Surface–
Associated ATP Synthase. Cancer Res.2006;66(2): 875-82.
53. Benelli R, Morini M, Carrozzino F, Ferrari N, Minghelli S, Santi L, et al:
Neutrophils as a key cellular target for angiostatin: implications for
regulation of angiogenesis and inflammation. FASEB J.2002;16:267269.
54. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9
triggers the angiogenic switch during carcinogenesis. Nat Cell
Biol.2000;2:737-744.
55. Hajitou A, Grignet C, Devy L, Berndt S, Blacher S, Deroanne CF, et al.
The antitumoal effect of endostatin and angiostatin is associated with a
down-regulation of vascular endothelial growth factor expression in
tumor cells. FASEB J.2002;1:1096-1102.
56. Redlitz A, Daum G, & Sage EH. Angiostatin diminishes activation of
the mitogen activated protein kinases ERK-1 and ERIC-2 in human
dermal microvascular endothelial cells. J Vase Res.1999;36:28-34.
57. Lucas R, et al. Multiple forms of angiostatin induce apoptosis in
endothelial cells. Blood.1998;92:4730-41.
58. Sharma MR. Angiostatin-induced inhibition of endothelial cell
proliferation/apoptosis is associated with the down-regulation of cell
cycle regulatory protein cdk5. J Cell Biochem.2004;91(2):398-409.
69
59. Veitonmaki N. et al. Endothelial cell surface ATP synthase-triggered
caspase-apoptotic
pathway
is
essential
for
kl-5-induced
antiangiogenesis. Cancer Res 2004;64:3679-86.
60. Lee TY, Muschal S, Pravda EA, Folkman J, Abdollahi A, Javaherian K.
Angiostatin regulates the expression of antiangiogenic and
proapoptotic pathways via targeted inhibition of mitochondrial
proteins. Blood 2009;114(9):1987-98.
61. Troyanovsky B, Levchenko T, Mansson G, Matvijenko O, Holmgren L.
Angiomotin: an angiostatin binding protein that regulates endothelial
cell migration and tube formation. J Cell Biol.2001;152:1247-54.
62. Tarui T, Miles LA, Takada Y. Specific interaction of angiostatin with
integrin
alpha(v)beta(3)
in
endothelial
cells.
J
Biol
Chem.2001;276:39562-8
63. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and
sustains dormancy of human primary tumors in mice. Nut
Med.1996;2:689-92.
64. Sten-Linder M, et al. Angiostatin fragments in urine from patients with
malignant disease. Anticancer Res.1999;19:3409-14.
65. Cao Y, et al. Elevated levels of urine angiostatin and
plasminogen/plasmin in cancer patients. Int JMol Med.2000;5:547-51.
66. Dahlan MS. Penelitian diagnostik: dasar-dasar teoretis dan aplikasi
dengan program SPSS dan Stata. Jakarta: Salemba Medika,2009:34
67. RayBio Human Angiostatin ELISA Kit Protocol. RayBiotech, Inc. User
Manual (Revised Mar 1, 2012)
68. ACOG. Manangement of adnexal masses. ACOG Practice Bulletin
2007;110(1):201-14
70
1. Antoniou A, Pharaoh PD, Narod S, et al. Average risks of breast and
ovarian cancer associated with BRCA1 or BRCA2 mutations detected
in case series unselected for family history: a combined analysis of 22
studies. Am J Hum Genet.2003;72(5):1117-30
2. World Cancer Research Fund / American Institute for Cancer
Research. Continuous Update Project Report. Food, Nutrition,
Physical Activity, and the Prevention of Ovarian Cancer 2014.
Available athttp://www.dietandcancerreport.org/cup/cup_resources.php
3. Jemal A, Siegel R, Ward E et al. Cancer statistics. CA Cancer J. Clin.
2008; 58(2):71–96.
4. du Bois A, Rochon J, Pfisterer J, Hoskins WJ. Variations in institutional
infrastructure, physician specialization and experience, and outcome in
ovarian cancer: a systematic review. Gynecol Oncol.2009;112:422-36.
5. Palmer C, et al. Systematic evaluation of candidate blood markers for
detecting ovarian cancer. PLoS One.2008;3:e2633
6. Blast L. Antigen cancer CA-125 in ovarian cancer. Am J Hum
Genet.1983;2
7. Zurawski VR, et al. An initial analysis of preoperative serum CA-125
levels in patients with early stage ovarian carcinoma. Gynecol
Oncol.1988;30:7-14
8. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A
risk of malignancy index incorporating CA-125, ultrasound and
menopausal status for the accurate preoperative diagnosis of ovarian
cancer. Br J Obstet Gynecol.1990;97:922-9
9. Van Holsbeke C, et al. Ultrasound methods to distinguish between
malignant and benign adnexal masses in the hands of examiners with
different
levels
of
experience.
Ultrasound
Obstet
Gynecol.2009;34:454-61.
10. Ferrara N. Vascular endothelial growth factor: basic science and
clinical progress. Endocr Rev.2004;25(4):581-611.
65
11. Zetter BR. Angiogenesis and tumor metastatis. Children’s Hospital.
Harvard Medical School. Boston. Massachusetts.1998;49:407-27
12. Oklu R, Walker TG, Wicky S, Hesketh R. Angiogenesis and current
antiangiogenic strategies for the treatment of cancer. Department of
Biochemistry University of Cambrige. United Kingdom.2010;21:19711805
13. Eskens FA. Angiogenesis inhibitors in clinical development; where are
we now and where are we going? Br J Cancer.2004;90:1-7.
14. Hazelton D, Nicosia RF, Nicosia SV. Vascular endothelial growth
factor levels in ovarian cyst fluid correlate with malignancy. Clin
Cancer Res.1999;5(4):823-9.
15. Yabushita H, Noguchi M, Obayashi Y, Kishida T, Noguchi Y,
Sawaguchi K, et al. Angiostatin expression in ovarian cancer. Oncol
Rep.2003;10(5):1225-30.
16. Urano T, Chibber B. A., Castellino F. J. The reciprocal effects of
epsilon-aminohexanoic acid and chloride ion on the activation of
human [Glu1]plasminogen by human urokinase. Proc. Natl. Acad. Sci.
U.S.A.1987;84:4031–4
17. Drenberg CD, Saunders BO, Wilbanks GD, Chen R, Nicosia RF, Kruk
PA, et al. Urinary angiostatin levels are elevated in patients with
epithelial ovarian cancer. Gynecologic Oncology.2010;117:117-124.
18. Damayana S. Perbedaan kadar angiostatin urin pada tumor ovarium
epitel jinak dan tumor ovarium epitel ganas. Tesis Peserta Pendidikan
Dokter Spesialis Obstetri dan Ginekologi Universitas Sumatera
Utara.2014.
19. Cunningham FG, Gant NF, Leveno KJ, Gilstrap LC, Hauth JC,
Wenstrom KD. Obstetri Williams Edisi ke-21 Vol. 2. Jakarta : ECG;
2004. p. 934,1035-7.
20. Berek JS, Satima N. Ovarian and fallopian tube cancer. Berek &
Novak’s Gynecology. Lippincott William and Wilkins. 14th ed. 2007:
1457-1503
21. WHO, GLOBOCAN, International agency of research and cancer.2008
22. FIGO Committee on Gynecologic Oncology, Denny L et al. Staging
classification and clinical practice guidelines for gynaecologic
cancers.2009.
66
23. Kurman RJ, Shih le-Ming. Pathogenesis of ovarian cancer: lessons
from morphology and molecular biology and their clinical implications.
Int J Gynecol Pathol.2008;27(2):151-60
24. Brohet RM, Goldgar DE, Easton DF, et al. Oral contraceptives and
breast cancer risk in the international BRCA1/2 carrier cohort study: a
report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS
collaborating group. J Clin Oncol.2007;25:3831-6
25. Rostgaard K. Does pregnancy induce the shedding of premalignat
ovarian cells? Epidemiology.2003;14:168-173
26. Whittermore AS. Characteristic relating to ovarian cancer risk,
Collaborating ovarian cancer group. Am J Epidemiol.1992;136:11841203
27. Cannistra SA, Gershenson DM, Recht A. Ovarian cancer, peritoneal
carcinoma and fallopian tube carcinoma. In: DeVita VT, Hellman S,
Rosenberg SA, eds. Cancer: Principles and practice of oncology. 8th
ed. Philadelpia, PA: Lippincott Williams & Wilkins; 2008:1569-94
28. Lynch HT, Casey MJ, Snyder CL, et al. Hereditary ovarian carcinoma:
Heterogeneity, molecular genetics, pathology and management and
hereditary
nonpolyposis
colorectal
cancer
(HNPCC).
Mol
Oncol.2009;3:97-137
29. Scully R, Sobin L. Histological typing of ovarian tumours, volume 9.
New York: Springer Berlin,1999.
30. Saifuddin, Abdul Bari, dkk. Ilmu Kebidanan Sarwono Prawirohardjo.
Jakarta: PT Bina Pustaka Sarwono Prawirohardjo. 2010.
31. Chen SS, Bochner R. Assesment of morbidity and mortality in primary
cytoreductive surgery for advanced ovarian carcinoma. Gynecol
Oncol.1985;20(2):190-5
32. Olivier RI, Lubsen-Brandsma MA, Verhoef S, et al. CA-125 and
transvaginal ultrasound monitoring in high risk women cannot prevent
the
diagnosis
of
advanced
ovarian
cancer.
Gynecol
Oncol.2006;100(1):20-26
33. Braun AH, Coffey RJ. Lysophosphatidic acid, a disintegrin and
metalloprotease-17 and heparin-binding epider- mal growth factor-like
growth factor in ovarian cancer: the first word, not the last. Clinical
Cancer Research.2005;11:4639–43.
67
34. Levine HA, Pamuk S, Sleeman BD, Hamilton MN. Mathematical
Modelling of Tumour Angiogenesis and the Action of Angiostatin as a
Protease Inhibitor. J Theoritical Med.2002; 4(2):133-45.
35. Shirakawa K, et al. Vasculogenic mimicry and pseudo-comedo
formation in breast cancer. Int J Cancer.2002;99:821–28
36. Baluk P, et al. Cellular abnormalities of blood vessels as targets in
cancer. Curr Opin Genet Dev.2005;15:102–11.
37. Cao Y. Therapeutic potentials of angiostatin in the treatment of cancer.
Haematologica.1999;84:643-650.
38. Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic
target for ovarian cancer therapy. Nature Clin Prac Oncol.2006; 5:194204.
39. Sim BKL, O'Reilly MS, Liang H, Fortier AH, He W, Madsen JW, et al. A
recombinant human angiostatin protein inhibits experimental primary
and metastatic cancer. Cancer Res.1997;57:1329–34.
40. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J
Med.1971;285(1):182-6.
41. Walter JJ, Sane DC. Angiostatin binds to smooth muscle cells in the
coronary artery and inhibits smooth muscle cell proliferation and
migration In vitro. ArteriosclerThromb Vasc Biol.1999;19:2041-8.
42. Morikawa W, Yamamoto K, Ishikawa S, Takemoto S, Ono M, Fukushi
J, Naito S, Nozaki C, Iwanaga S, and Kuwano M. Angiostatin
generation by cathepsin D secreted by human prostate carcinoma
cells. J. Biol. Chem.2000;275: 38912–20.
43. Ji WR, Castellino FJ, Chang Y, Deford ME, Gray H, Villarreal X, et al.
Characterization of kringle domains of angiostatin as antagonists of
endothelial cell migration, an important process in angiogenesis.
FASEB.1998;12(15):1731-8.
44. Cao Y, Chen A, An SS, Ji RW, Davidson D, Llinas M: Kringle 5 of
plasminogen is a novel inhibitor of endothelial cell growth. J Biol
Chem.1997;272(36):22924-8.
45. Wahl ML, Kenan DJ, Gronow GM, Pizzo SV. Angiostatin's molecular
mechanism: aspects of specificity and regulation elucidated. J Cell
Biochem.2005;96(2):242-61.
46. Warejcka D. Angiostatin used as an assay standard in a cell
proliferation assay. Biochem. J.2005;392:703–12.
68
47. Soff GA. Angiostatin and angiostatin-related
Metastasis Rev.2000;19(1-2):97-107.
proteins.
Cancer
48. O'Reilly MS. et al. Angiostatin: a novel angiogenesis inhibitor that
mediates the suppression of metastases by a Lewis lung carcinoma.
Cell.1994;79:315-28.
49. Cao R, Wu HL, Veitonmaki N, Linden P, Farnebo J, Shi GY, et al:
Suppression of angiogenesis and tumor growth by the inhibitor K1–5
generated by plasmin-mediated proteolysis. Proc Natl Acad Sci
USA.1999;96:5728-5733.
50. Schulter V, et al. Impact of apolipoprotein(a) on in vitro angiogenesis.
Arterioscler Thromb Vasc Biol.2001;21:433-8.
51. Mowery YM, Pizzo
2009;114(9):1727-8
SV.
The
antitumorigenic
trifecta.
Blood
52. Chi SL, Pizzo SV. Angiostatin Is Directly Cytotoxic to Tumor Cells at
Low Extracellular pH: A Mechanism Dependent on Cell Surface–
Associated ATP Synthase. Cancer Res.2006;66(2): 875-82.
53. Benelli R, Morini M, Carrozzino F, Ferrari N, Minghelli S, Santi L, et al:
Neutrophils as a key cellular target for angiostatin: implications for
regulation of angiogenesis and inflammation. FASEB J.2002;16:267269.
54. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9
triggers the angiogenic switch during carcinogenesis. Nat Cell
Biol.2000;2:737-744.
55. Hajitou A, Grignet C, Devy L, Berndt S, Blacher S, Deroanne CF, et al.
The antitumoal effect of endostatin and angiostatin is associated with a
down-regulation of vascular endothelial growth factor expression in
tumor cells. FASEB J.2002;1:1096-1102.
56. Redlitz A, Daum G, & Sage EH. Angiostatin diminishes activation of
the mitogen activated protein kinases ERK-1 and ERIC-2 in human
dermal microvascular endothelial cells. J Vase Res.1999;36:28-34.
57. Lucas R, et al. Multiple forms of angiostatin induce apoptosis in
endothelial cells. Blood.1998;92:4730-41.
58. Sharma MR. Angiostatin-induced inhibition of endothelial cell
proliferation/apoptosis is associated with the down-regulation of cell
cycle regulatory protein cdk5. J Cell Biochem.2004;91(2):398-409.
69
59. Veitonmaki N. et al. Endothelial cell surface ATP synthase-triggered
caspase-apoptotic
pathway
is
essential
for
kl-5-induced
antiangiogenesis. Cancer Res 2004;64:3679-86.
60. Lee TY, Muschal S, Pravda EA, Folkman J, Abdollahi A, Javaherian K.
Angiostatin regulates the expression of antiangiogenic and
proapoptotic pathways via targeted inhibition of mitochondrial
proteins. Blood 2009;114(9):1987-98.
61. Troyanovsky B, Levchenko T, Mansson G, Matvijenko O, Holmgren L.
Angiomotin: an angiostatin binding protein that regulates endothelial
cell migration and tube formation. J Cell Biol.2001;152:1247-54.
62. Tarui T, Miles LA, Takada Y. Specific interaction of angiostatin with
integrin
alpha(v)beta(3)
in
endothelial
cells.
J
Biol
Chem.2001;276:39562-8
63. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and
sustains dormancy of human primary tumors in mice. Nut
Med.1996;2:689-92.
64. Sten-Linder M, et al. Angiostatin fragments in urine from patients with
malignant disease. Anticancer Res.1999;19:3409-14.
65. Cao Y, et al. Elevated levels of urine angiostatin and
plasminogen/plasmin in cancer patients. Int JMol Med.2000;5:547-51.
66. Dahlan MS. Penelitian diagnostik: dasar-dasar teoretis dan aplikasi
dengan program SPSS dan Stata. Jakarta: Salemba Medika,2009:34
67. RayBio Human Angiostatin ELISA Kit Protocol. RayBiotech, Inc. User
Manual (Revised Mar 1, 2012)
68. ACOG. Manangement of adnexal masses. ACOG Practice Bulletin
2007;110(1):201-14
70